These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407 [TBL] [Abstract][Full Text] [Related]
3. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis. Steinmaurer A; Riedl C; König T; Testa G; Köck U; Bauer J; Lassmann H; Höftberger R; Berger T; Wimmer I; Hametner S Brain Pathol; 2024 Sep; 34(5):e13240. PubMed ID: 38254312 [TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression? Geladaris A; Torke S; Weber MS CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589 [TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis. Saberi D; Geladaris A; Dybowski S; Weber MS Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515 [TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination. Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842 [TBL] [Abstract][Full Text] [Related]
7. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Zhou J; Cai W; Jin M; Xu J; Wang Y; Xiao Y; Hao L; Wang B; Zhang Y; Han J; Huang R Sci Rep; 2015 Sep; 5():13713. PubMed ID: 26329786 [TBL] [Abstract][Full Text] [Related]
8. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Cignarella F; Filipello F; Bollman B; Cantoni C; Locca A; Mikesell R; Manis M; Ibrahim A; Deng L; Benitez BA; Cruchaga C; Licastro D; Mihindukulasuriya K; Harari O; Buckland M; Holtzman DM; Rosenthal A; Schwabe T; Tassi I; Piccio L Acta Neuropathol; 2020 Oct; 140(4):513-534. PubMed ID: 32772264 [TBL] [Abstract][Full Text] [Related]
10. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Bhargava P; Kim S; Reyes AA; Grenningloh R; Boschert U; Absinta M; Pardo C; Van Zijl P; Zhang J; Calabresi PA Brain; 2021 Jun; 144(5):1396-1408. PubMed ID: 33724342 [TBL] [Abstract][Full Text] [Related]
11. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis. Wen J; Ribeiro R; Tanaka M; Zhang Y Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763 [TBL] [Abstract][Full Text] [Related]
12. Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis. Turner TJ; Brun P; Gruber RC; Ofengeim D Drugs R D; 2024 Jun; 24(2):263-274. PubMed ID: 38965189 [TBL] [Abstract][Full Text] [Related]
13. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912 [TBL] [Abstract][Full Text] [Related]
14. Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Elkjaer ML; Waede MR; Kingo C; Damsbo K; Illes Z Front Immunol; 2023; 14():1264128. PubMed ID: 38022591 [TBL] [Abstract][Full Text] [Related]
15. Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery. Nissen JC; Thompson KK; West BL; Tsirka SE Exp Neurol; 2018 Sep; 307():24-36. PubMed ID: 29803827 [TBL] [Abstract][Full Text] [Related]
16. Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination. Pennati A; Nylen EA; Duncan ID; Galipeau J J Neurosci; 2020 Jun; 40(26):5105-5115. PubMed ID: 32430295 [TBL] [Abstract][Full Text] [Related]
17. Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. Weinger JG; Brosnan CF; Loudig O; Goldberg MF; Macian F; Arnett HA; Prieto AL; Tsiperson V; Shafit-Zagardo B J Neuroinflammation; 2011 May; 8():49. PubMed ID: 21569627 [TBL] [Abstract][Full Text] [Related]